Loading icon
Press enter or spacebar to select a desired language.
Research
Press enter or spacebar to select a desired language.

PubMed COVID-19 Clinical Care

3661 - 3670 of 44782 results found

An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis

Date
Wednesday, February 07, 2024 - 4:00 AM
Description
CONCLUSIONS: After 16 weeks of once- or twice-daily oral administration, treatment with the interleukin-23-receptor antagonist peptide JNJ-77242113 showed greater efficacy than placebo in patients with moderate-to-severe plaque psoriasis. (Funded by